Inicio/Acciones/IXHL

IXHL

USD

Incannex Healthcare Inc. Common Stock

$0.339-0.005 (-1.480%)

Precio en Tiempo Real

Healthcare

Drug Manufacturers - Specialty & Generic

Australia

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado

Fundamentos de la Empresa

Estadísticas de Negociación

Métricas de Mercado

Apertura

$0.344

Máximo

$0.349

Mínimo

$0.336

Volumen

15.84M

Fundamentos de la Empresa

Capitalización de Mercado

118.0M

Industria

Drug Manufacturers - Specialty & Generic

País

Australia

Estadísticas de Negociación

Volumen Promedio

66.44M

Bolsa

NCM

Moneda

USD

Rango de 52 Semanas

Mínimo $0.08Actual $0.339Máximo $3.12

Noticias Relacionadas

26 ago 2025 · 12:00

GlobeNewswire

Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder

MELBOURNE, Australia and NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company") is pleased to report positive data from its Phase 2 clinical trial of PSX-001

Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder

22 ago 2025 · 12:00

GlobeNewswire

Incannex Healthcare Authorizes $20 Million Share Repurchase Program

MELBOURNE, Australia and NEW YORK, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company developing innovative combination

Incannex Healthcare Authorizes $20 Million Share Repurchase Program

8 ago 2025 · 12:00

GlobeNewswire

Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea

MELBOURNE, Australia and NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage pharmaceutical company developing innovative combination therapies for prevalent medical